PapersFlow Research Brief
Pharmaceutical Economics and Policy
Research Guide
What is Pharmaceutical Economics and Policy?
Pharmaceutical Economics and Policy is the study of economic factors in pharmaceutical research and development, including drug development costs, generic drugs, innovation incentives, medicine prices, patent expiry, healthcare policies, market size, medicine availability, and generic substitution.
The field encompasses 78,270 works analyzing the economics of pharmaceuticals. Key areas include drug development costs, generic drugs, pharmaceutical innovation, medicine prices, patent expiry, healthcare policies, market size, availability of medicines, and generic substitution. Growth rate over the last 5 years is not available.
Topic Hierarchy
Research Sub-Topics
Drug Development Costs
This sub-topic analyzes the financial, time, and risk components of bringing new pharmaceuticals to market, including R&D expenditure estimation models. Researchers model cost structures across phases and assess impacts of failures and regulatory delays.
Pharmaceutical Innovation Economics
This sub-topic examines drivers of innovation such as patents, market exclusivity, and public funding in pharmaceutical R&D. Researchers quantify returns on investment and evaluate incentives for novel drug discovery.
Generic Drug Market Dynamics
This sub-topic studies competition, entry barriers, and pricing behaviors following patent expiry in generic pharmaceuticals. Researchers analyze market concentration, substitution rates, and impacts on originator drug revenues.
Pharmaceutical Pricing Policies
This sub-topic explores regulatory mechanisms like price controls, negotiation, and reference pricing in pharmaceutical markets. Researchers assess effects on supply, innovation, and patient access across countries.
Patent Expiry Effects on Pharmaceuticals
This sub-topic investigates economic consequences of patent cliffs, including revenue loss and generic competition strategies. Researchers model transition periods and strategies for lifecycle management.
Why It Matters
Pharmaceutical Economics and Policy informs decisions on drug pricing and innovation incentives, directly affecting healthcare costs and patient access. DiMasi et al. (2003) in "The price of innovation: new estimates of drug development costs" estimated high costs of bringing new drugs to market, influencing policy debates on R&D incentives and pricing regulations. Arrow (2003) in "UNCERTAINTY AND THE WELFARE ECONOMICS OF MEDICAL CARE" analyzed uncertainties in medical care markets, shaping policies for insurance and resource allocation in pharmaceuticals. Kola and Landis (2004) in "Can the pharmaceutical industry reduce attrition rates?" examined high failure rates in drug development, guiding industry strategies to improve efficiency and reduce costs passed to consumers.
Reading Guide
Where to Start
"The price of innovation: new estimates of drug development costs" by DiMasi et al. (2003), as it provides foundational estimates of R&D costs central to understanding economic incentives in pharmaceuticals.
Key Papers Explained
DiMasi et al. (2003) in "The price of innovation: new estimates of drug development costs" establishes baseline R&D cost figures, which Kola and Landis (2004) in "Can the pharmaceutical industry reduce attrition rates?" builds on by analyzing failure rates that drive those costs. Arrow (2003) in "UNCERTAINTY AND THE WELFARE ECONOMICS OF MEDICAL CARE" provides the theoretical framework of market uncertainties underpinning both empirical works.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current frontiers focus on empirical analysis of drug development costs, attrition reduction strategies, and welfare economics of uncertainty, as no recent preprints or news are available.
Papers at a Glance
Frequently Asked Questions
What are the estimated costs of drug development?
DiMasi et al. (2003) in "The price of innovation: new estimates of drug development costs" provided new estimates of drug development costs. These estimates account for the full process from discovery to market approval. The study highlights the financial risks involved in pharmaceutical innovation.
How does uncertainty affect medical care economics?
Arrow (2003) in "UNCERTAINTY AND THE WELFARE ECONOMICS OF MEDICAL CARE" explains that uncertainty distinguishes medical care markets from competitive models. This uncertainty impacts resource allocation and welfare outcomes in pharmaceuticals. Policies must address these market failures to improve efficiency.
What factors contribute to high attrition rates in pharmaceuticals?
Kola and Landis (2004) in "Can the pharmaceutical industry reduce attrition rates?" identify reasons for high drug candidate failure rates during development. Reducing attrition requires better target selection and preclinical testing. Lower attrition would decrease overall development costs.
Why study generic drugs and patent expiry in pharmaceutical economics?
Generic drugs and patent expiry lower medicine prices and increase availability after brand-name exclusivity ends. These processes are central to balancing innovation incentives with affordable access. Policies on generics promote substitution and market competition.
What role do healthcare policies play in pharmaceutical markets?
Healthcare policies regulate medicine prices, patents, and generic substitution to influence market size and innovation. They address issues like drug development costs and availability of medicines. Effective policies ensure both R&D investment and patient access.
Open Research Questions
- ? How can drug development costs be accurately estimated while accounting for opportunity costs and success probabilities?
- ? What policy interventions best balance innovation incentives with affordable medicine prices post-patent expiry?
- ? How do high attrition rates in clinical trials impact overall pharmaceutical R&D efficiency?
- ? In what ways does market uncertainty necessitate non-competitive structures in pharmaceutical economics?
- ? Which factors most influence generic substitution rates and their effects on healthcare expenditures?
Recent Trends
The field includes 78,270 works with no specified 5-year growth rate.
Top-cited papers such as DiMasi et al. with 4263 citations continue to shape discussions on drug development costs.
2003No recent preprints or news coverage from the last 12 months or 6 months indicate stable focus on established topics like attrition rates from Kola and Landis .
2004Research Pharmaceutical Economics and Policy with AI
PapersFlow provides specialized AI tools for Economics, Econometrics and Finance researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Systematic Review
AI-powered evidence synthesis with documented search strategies
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Economics & Business use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pharmaceutical Economics and Policy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Economics, Econometrics and Finance researchers